Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.6 USD | -3.76% | +10.19% | +55.15% |
May. 06 | Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024 | |
May. 06 | Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M | MT |
Evolution of the average Target Price on Enanta Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Enanta Pharmaceuticals, Inc.
Oppenheimer | |
HC Wainwright | |
RBC Capital Markets | |
JMP Securities | |
Jefferies & Co. | |
JPMorgan Chase | |
SVB Securities LLC | |
Evercore ISI | |
Baird | |
Roth Capital Partners | |
SVB Leerink | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- ENTA Stock
- Consensus Enanta Pharmaceuticals, Inc.